Pfizer Inc. (NYSE:PFE) Shares Sold by Game Creek Capital LP

Game Creek Capital LP reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 233,375 shares of the biopharmaceutical company's stock after selling 35,625 shares during the period. Pfizer makes up approximately 2.4% of Game Creek Capital LP's investment portfolio, making the stock its 3rd biggest holding. Game Creek Capital LP's holdings in Pfizer were worth $6,191,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Gotham Asset Management LLC lifted its stake in shares of Pfizer by 333.4% during the fourth quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company's stock worth $3,742,000 after buying an additional 108,494 shares during the period. Focus Partners Wealth lifted its position in Pfizer by 65.6% during the fourth quarter. Focus Partners Wealth now owns 1,311,901 shares of the biopharmaceutical company's stock valued at $35,077,000 after purchasing an additional 519,522 shares during the period. Forefront Analytics LLC lifted its position in Pfizer by 4.3% during the fourth quarter. Forefront Analytics LLC now owns 14,903 shares of the biopharmaceutical company's stock valued at $395,000 after purchasing an additional 609 shares during the period. Ensign Peak Advisors Inc lifted its position in Pfizer by 27.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 6,445,011 shares of the biopharmaceutical company's stock valued at $170,986,000 after purchasing an additional 1,383,305 shares during the period. Finally, Ethic Inc. lifted its position in Pfizer by 40.4% during the fourth quarter. Ethic Inc. now owns 449,474 shares of the biopharmaceutical company's stock valued at $11,925,000 after purchasing an additional 129,381 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PFE shares. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

Shares of PFE traded up $0.81 during mid-day trading on Monday, hitting $23.09. 77,367,014 shares of the company were exchanged, compared to its average volume of 40,672,229. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50 day moving average of $24.02 and a 200-day moving average of $25.52. The stock has a market cap of $131.25 billion, a price-to-earnings ratio of 16.37, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The company's revenue for the quarter was down 7.8% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.45%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.